President & CEO
Mr. McNally is the President and Chief Executive Officer of Titan Medical Inc. Mr. McNally is an experienced entrepreneur and public company CEO. Since co-founding his first company at the age of 25, Mr. McNally has been inspired to make a difference in the medical industry.
He enjoys helping patients and caregivers, collaborating with global thinkers and creating a workplace that brings out the best in everyone.
Throughout his career, Mr. McNally has founded, co-founded and led early-stage medical device companies that commercialized best-in-class surgical, life and organ support, diagnostic and home-care capital equipment, as well as disposables. Among other accomplishments, he has experience leading companies trading on boards ranging from over-the-counter marketplaces to the TSX and Nasdaq exchanges.
Mr. McNally also has experience in U.S. FDA regulatory clearances and EU CE mark for Class II devices, as well as establishing and managing relationships with strategic partners including OEM suppliers and global distributors.
Mr. McNally is formerly the founder, President, CEO and Chairman of Domain Surgical Inc., a developer, manufacturer and marketer of advanced energy surgical platforms, which merged with OmniGuide Holdings, Inc. in 2016. Mr. McNally was co-founder, President and CEO of ZEVEX International Inc. (Nasdaq: ZVXI), a developer, manufacturer and marketer of award-winning medical devices, which was acquired by MOOG Inc. in 2007.
Mr. McNally earned an MBA from the University of Utah and holds a Bachelor of Science degree in Mechanical Engineering from Lafayette College, Easton, PA. He is the co-inventor of more than 40 U.S. and international patents associated with robotic surgical systems, ferromagnetic surgical devices and systems, electromagnetic and ultrasonic sensors, as well as medical fluid delivery systems.
Chief Financial Officer
Mr. Lemieux has more than 18 years of experience in public companies including over 9 years as a Chief Financial Officer and 13 years in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at over $400 million. Mr. Lemieux served as CFO and Secretary of NeuPath Health (TSXV: NPTH) from 2019 to 2021.
Prior to NeuPath, Mr. Lemieux served as the CFO and Secretary at Cipher Pharmaceuticals (TSX:CPH) from 2016 to 2019 and acted as Interim-CEO from November 2016 to April 2017. Prior to Cipher Pharmaceuticals, Mr. Lemieux was CFO at Nuvo Pharmaceuticals (TSX:NRI) and Crescita Therapeutics (TSX:CTX). Crescita was created on March 1, 2016 by way of a plan of arrangement that reorganized Nuvo Research Inc. into Nuvo and Crescita. Mr. Lemieux is a Chartered Professional Accountant and holds a Master of Management & Professional Accounting degree from the University of Toronto.
Perry Genova, PhD
Senior Vice President, Research and Development & President of Titan Medical USA Inc.
Dr. Genova is an accomplished, innovative, and seasoned executive who, over a career spanning 30 years, has been recognized for building and leading successful teams in both small and multi-national companies. He has led four medical device startup companies and has broad expertise across pharmaceutical, medical device, and consumer product industries.
He received PhD and Master of Science degrees in Biomedical Engineering from the University of North Carolina (UNC) at Chapel Hill and a Bachelor of Science degree in Electrical Engineering from UNC Charlotte. Dr. Genova is a co-inventor on 55 issued and pending U.S. patents and co-author of over 30 scientific papers and presentations.
Vice President, Strategy & Business Development
Mr. Basra joins Titan with over 20 years’ experience in global Business Development and Mergers and Acquisitions (M&A). Latterly working as a Board Member and Business Advisor for early-stage companies, his corporate experience includes serving as Vice President of Business Development and Licensing for Covidien’s Vascular Therapies division, and Senior Vice President, Strategy and Business Development at Smith & Nephew.
Prior to that, Mr. Basra worked in the Telecommunications industry and held various Business Development roles at Cable & Wireless, British Telecommunications PLC, and Phillips. Mr. Basra holds a Bachelor of Science from Edinburgh University and a Master of Business Administration from Henley Management College, UK.
Vice President, Legal, IP and Strategic Initiatives, General Counsel
Mr. Brar draws from more than 15 years of technical, business and legal experience to manage Titan’s legal affairs while leading and executing a comprehensive IP program that facilitates innovation, enhances business objectives and mitigates risks. Working alongside other Titan executives, engineering teams and advisers, Mr. Brar ensures that the company’s IP strategy remains in alignment with – and continues to influence and enhance – the company’s overall business strategy.
Before joining Titan, Mr. Brar practiced with the law firm of Smart & Biggar in Vancouver, British Columbia. Before practicing law, he worked as an engineer and in product marketing with National Semiconductor in Santa Clara, California. Mr. Brar is deeply passionate about innovation that enhances people’s quality of life and the role of intellectual property in driving, supporting and testing such innovation. He has a Law degree (LL.B.) and a Bachelor of Science degree in Computer Engineering, both from the University of Manitoba.
Vice President, Quality and Regulatory Affairs
Ms. Carrea has more than 25 years of experience in managing quality assurance and regulatory affairs activities in the medical device industry, including robotic assisted surgery. Ms. Carrea has been responsible for global submissions and registrations for Class 1, 2, and 3 medical devices including De Novo applications.
Ms. Carrea served as Vice President, Regulatory and Clinical Affairs and Security Officer of Translational Imaging Innovations, Inc, from 2019 to 2021. Prior to this, she served as Vice President, Quality and Regulatory at Baebies, Inc, from 2016 to 2019. In 2015, she served as Director, Quality and Regulatory Affairs for Bioptigen. From 2009-2014, Ms. Carrea was Vice President Quality Assurance and Regulatory Affairs at TransEnterix Inc, (now Asensus Surgical Inc, NYSE American: ASXC). Ms. Carrea holds a Bachelor of Science Degree in Materials Science and Engineering from North Carolina State University, and a Master of Science Degree in Quality and Regulatory Affairs from Temple University, with a concentration in medical devices and clinical research.
Vice President, Investor Relations & Corporate Communications
Ms. Galfetti has over 20 years of experience leading investor relations and corporate communications programs. Most recently, Ms. Galfetti provided consulting services to small and medium companies in the life science industries.
Her corporate experience includes serving as Vice President, Investor Relations & Corporate Communications at Cynapsus Therapeutics. Prior to Cynapsus, she was Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director, Corporate Communications and Investor Relations at AMAG Pharmaceuticals. Prior to AMAG, Ms. Galfetti held Investor Relations roles of increasing responsibility at Genzyme Corporation. Ms. Galfetti holds a Bachelor of Arts in Political Science from the University of Vermont and a Master of Business Administration (with distinction) from Bentley University.
Vice President, Finance
Mr. Huang is a financial executive with over 20 years of experience developing and implementing financial models and systems, and accounting practices to support the achievement of strategic corporate objectives.
Mr. Huang has strong expertise in evaluating investment opportunities and long-term value creation as well as extensive knowledge of IFRS and U.S. GAAP reporting requirements. Most recently, he served as Senior Vice President, Corporate Finance at Quarterhill Inc., where he led the finance systems migration and reorganized key business processes, streamlining external reporting processes. Prior to Quarterhill, Mr. Huang served as Vice President, Finance at Aralez Pharmaceuticals, responsible for implementing systems upgrades, negotiating potential divestitures and advising on private equity financing. Prior to this, Mr. Huang was Senior Director, Finance at Astellas Pharma. Mr. Huang holds a Bachelor of Science in Physiology from the University of Toronto, a Graduate Diploma in Public Accountancy from McGill University, and has Chartered Accountant Designation.
Vice President, Upstream Marketing
Mr. Seibert has 16+ years of experience in the medical device industry, spanning clinical sales, sales leadership, strategic planning and product development at companies ranging from those with a very mature product lifecycle to early stage, pre-submission products.
Mr. Seibert has spent 15 years focusing on robotic medical devices, including stints of increasing levels of responsibility at both Intuitive Surgical, Inc., and Stereotaxis, Inc. Mr. Seibert has an in-depth, national network of innovative physicians and healthcare executives. He has worked for four start-up companies and has extensive relationships across the IDN/GPO landscape. Mr. Seibert has a Bachelor of Arts from the University of Alabama, a Master of Arts in Human Relations from the University of Oklahoma and an MBA from the University of South Alabama.